BGI, Merck Agree to Explore Areas of Interest in Next-gen Sequencing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BGI today announced that it has signed a statement of intent with drug giant Merck to explore areas of mutual interest with the goal of "creating value" from the high volume of information resulting from next-generation sequencing technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.